Novartis Gives Up On Rituxan Biosimilar For US Market

 
• By Kevin Grogan and Alexandra Shimmings
  
Boxing
Novartis calls it quits on Rituxan biosimilar • Source: Shutterstock

More from Anticancer

More from Therapy Areas